J. Goldman & CO LP Trevi Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
A detailed history of J. Goldman & CO LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 792,806 shares of TRVI stock, worth $8.98 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
792,806
Previous 979,098
19.03%
Holding current value
$8.98 Million
Previous $5.36 Million
32.34%
% of portfolio
0.21%
Previous 0.14%
Shares
8 transactions
Others Institutions Holding TRVI
# of Institutions
174Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...